Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Oxaprozin (compound)

Summary
General Info

PubChem

PubChem Compound 4614

PubChem Compound 4614

Name:	oxaprozin
PubChem Compound ID:	4614
Molecular formula:	C₁₈H₁₅NO₃
Molecular weight:	293.317 g/mol
Synonyms:	Xopane; NCI60_002681; 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid; Oxaprozina [INN-Spanish]; SPBio_001652; Duraprox; NSC 310839; KBioGR_001722; WY 21743; NCIStruc2_000787. show more » Xopane; NCI60_002681; 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid; Oxaprozina [INN-Spanish]; SPBio_001652; Duraprox; NSC 310839; KBioGR_001722; WY 21743; NCIStruc2_000787; 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid; Lopac-O-9637; NSC-310839; 4, 5-Diphenyl-2-oxazolepropionic acid; Maybridge1_008800; EINECS 244-296-1; SPBio_002940; AIDS128972; NCGC00014711-02; 4,5-Diphenyl-2-oxazolepropanoic acid; NCGC00014711-03; Daypro; KBio3_001916; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; Prestwick0_001060; Oxaprozin (JP15/USAN); Spectrum2_001696; AIDS-128972; Wy-21743; NCIStruc1_000799; 21256-18-8; WY-21,743; Spectrum4_001231; CAS-21256-18-8; Oxaprozin; Spectrum3_001078; BRN 1083168; C07356; .Beta.-(4,5-Diphenyloxazol-2-yl)propionic acid; Alvo; Deflam; Daypro (TN); 2-Oxazolepropionic acid, 4,5-diphenyl-; nsc310839; EU-0100944; Oxaprozin [USAN:BAN:INN:JAN]; D00463; Voir; NCGC00014711; Oxaprozinum [INN-Latin]; Prestwick1_001060; 4,5-Diphenyl-2-oxazolepropionic acid; Oxaprozine [INN-French]; 2-Oxazolepropanoic acid, 4,5-diphenyl-; beta-(4,5-Diphenyloxazol-2-yl)propionic acid; Actirin show less «

DrugBank

Identification

Name:	oxaprozin
Name (isomeric):	DB00991
Drug Type:	small molecule
Synonyms:	Oxaprozine [INN-French]; Oxaprozina [INN-Spanish]; Oxaprozinum [INN-Latin]
Brand:	Deflam, Voir, Daypro, Daypro Alta, Alvo
Category:	Anti-inflammatory Agents, Nonsteroidal Anti-inflammatory Agents (NSAIAs)
CAS number:	21256-18-8

Pharmacology

Indication:	Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
Pharmacology:	Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Mechanism of Action:	Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective N... show more » Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity. show less «
Absorption:	Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
Protein binding:	>99.5% bound to albumin
Biotransformation:	Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.
Route of elimination:	Oxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
Half Life:	54.9 hours
Toxicity:	Oral, mouse: LD₅₀ = 1210 mg/kg; Oral, rabbit: LD₅₀ = 172 mg/kg; Oral, rat: LD₅₀ = 4470 mg/kg
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.

Drug interaction:

Dicumarol	The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol.
Treprostinil	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy.
Warfarin	The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Telmisartan	Concomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
Timolol	The NSAID, Oxaprozin, may antagonize the antihypertensive effect of Timolol.

Targets

Prostaglandin G/H synthase 1

Prostaglandin G/H synthase 2

Enzymes

Cytochrome P450 2C9